Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 722, Issue 2, 2011, Pages 154-164

  Balasubramani, Manimalha ^a   Nakao, Chitose ^b   Uechi, Guy T ^a   Cardamone, John ^a   Kamath, Kathy ^b   Leslie, Kristen L ^a   Balachandran, Raghavan ^a   Wilson, Leslie ^b   Day, Billy W ^a   Jordan, Mary Ann ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Microtubule dynamics; Mitosis; Proteomics; Resistance; Stathmin; Taxol

Indexed keywords

PACLITAXEL; POLYMER; STATHMIN;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; DRUG ACTIVITY; DRUG SENSITIVITY; GEL; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS; MOLECULAR CLONING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MICROTUBULES; MITOSIS; MITOTIC INDEX; NEOPLASM PROTEINS; PACLITAXEL; STATHMIN; UP-REGULATION;

EID: 79957784767     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2010.08.019     Document Type: Article

References (45)

1. Orr G.A., Verdier-Pinard P., McDaid H., Horwitz S.B. Mechanisms of taxol resistance related to microtubules. Oncogene 2003, 22:7280-7295.
2. Holmfeldt P., Sellin M.E., Gullberg M. Predominant regulators of tubulin monomer-polymer partitioning and their implication for cell polarization. Cell Mol. Life Sci. 2009, 66:3263-3276.
3. Belmont L.D., Mitchison T.J. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996, 84:623-631.
4. Howell B., Deacon H., Cassimeris L. Decreasing oncoprotein 18/stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo. J. Cell Sci. 1999, 112:3713-3722.
5. Howell B., Larsson N., Gullberg M., Cassimeris L. Dissociation of the tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 18/stathmin. Mol. Biol. Cell 1999, 10(1999):105-118.
6. Larsson N., Segerman B., Howell B., Fridell K., Cassimeris L., Gullberg M. Op18/stathmin mediates multiple region-specific tubulin and microtubule-regulating activities. J. Cell Biol. 1999, 146:1289-1302.
7. Steinmetz M.O., Kammerer R.A., Jahnke W., Goldie K.N., Lustig A., van Oostrum J. Op18/stathmin caps a kinked protofilament-like tubulin tetramer. EMBO J. 2000, 19:572-580.
8. Manna T., Thrower D., Miller H.P., Curmi P., Wilson L. Stathmin strongly increases the minus end catastrophe frequency and induces rapid treadmilling of bovine brain microtubules at steady state in vitro. J. Biol. Chem. 2006, 281:2071-2078.
9. Alli E., Bash-Babula J., Yang J.M., Hait W.N. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002, 62:6864-6869.
10. Unlu M., Morgan M.E., Minden J.S. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18:2071-2077.
11. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82:1107-1112.
12. Kamath K., Jordan M.A. Suppression of microtubule dynamics by epothilone B in living MCF7 cells. Cancer Res. 2003, 63:6026-6031.
13. Beckner M.E., Chen X., An J., Day B.W., Pollack I.F. Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab. Invest. 2005, 85:316-327.
14. Jordan M.A., Toso R.J., Thrower D., Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:9552-9556.
15. Marklund U., et al. The phenotype of a " Cdc2 kinase target site-deficient mutant" of oncoprotein 18 reveals a role of this protein in cell cycle control. J. Biol. Chem. 1994, 269:30626-30635.
16. Curmi P.A., Noguès C., Lachkar S., Carelle N., Gonthier M.P., Sobel A., Lidereau R., Bièche I. Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br. J. Cancer 2000, 82:142-150.
17. Price D.K., Ball J.R., Bahrani-Mostafavi Z., Vachris J.C., Kaufman J.S., Naumann R.W., Higgins R.V., Hall J.B. The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest. 2000, 18:722-730.
18. Horwitz S., Shen H.J., He L., Dittmar P., Neef R., Chen J., Schubart U.K. The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation. J. Biol. Chem. 1997, 272:8129-8132.
19. Gavet O., Ozon S., Manceau V., Lawler S., Curmi P., Sobel A. The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network. J. Cell Sci. 1998, 111:3333-3346.
20. Marklund U., Larsson N., Gradin H.M., Brattsand G., Gullberg M. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J. 1996, 15:5290-5298.
21. 2+/calmodulin-dependent kinase IV/Gr-dependent phosphorylation of oncoprotein 18. Mol. Cell. Biol. 1997, 17:3459-3467.
22. Ringhoff D.N., Cassimeris L. Stathmin regulates centrosomal nucleation of microtubules and tubulin dimer/polymer partitioning. Mol. Biol. Cell 2009, 20:3451-3458.
23. Arnal I., Karsenti E., Hyman A. Structural transitions at microtubule ends correlate with their dynamic properties in Xenopus egg extracts. J. Cell Biol. 2000, 149:767-774.
24. Jordan M., Kamath K. How do microtubule-targeted drugs work? An overview. Curr. Cancer Drug Targets 2007, 7:730-742.
25. Chuthapisith S., Layfield R., Kerr I.D., Hughes C., Eremin O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int. J. Oncol. 2007, 30:1545-1551.
26. Cicchillitti L., Di Michele M., Urbani A., Ferlini C., Donat M.B., Scambia G., Rotilio D. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J. Proteome Res. 2009, 8:1902-1912.
27. Di Michele M., Della Corte A., Cicchillitti L., Del Boccio P., Urbani A., Ferlini C., Scambia G., Donati M.B., Rotilio D. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim. Biophys. Acta 2009, 1794:225-236.
28. Martinkova J., Gadher S.J., Hajduch M., Kovarova H. Challenges in cancer research and multifaceted approaches for cancer biomarker quest. FEBS Lett. 2009, 583:1772-1784.
29. Chen S.T., Pan T.L., Tsai Y.C., Huang C.M. Proteomics reveals protein profile changes in doxorubicin--treated MCF-7 human breast cancer cells. Cancer Lett. 2002, 181:95-107.
30. Poland J., Schadendorf D., Lage H., Schnölzer M., Celis J.E., Sinha P. Study of therapy resistance in cancer cells with functional proteome analysis. Clin. Chem. Lab. Med. 2002, 40:221-234.
31. Somiari R.I., Sullivan A., Russell S., Somiari S., Hu H., Jordan R., George A., Katenhusen R., Buchowiecka A., Arciero C., Brzeski H., Hooke J., Shriver C. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 2003, 3:1863-1873.
32. Urbani A., Poland J., Bernardini S., Bellincampi L., Biroccio A., Schnölzer M., Sinha P., Federici G. A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 2005, 5:796-804.
33. Yan X.D., Pan L.Y., Yuan Y., Lang J.H., Mao N. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J. Proteome Res. 2007, 6:772-780.
34. Keenan J., Murphy L., Henry M., Meleady P., Clynes M. Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 2009, 9:1556-1566.
35. Dowling P, Meleady P., Dowd A., Henry M., Glynn S., Clynes M. Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim. Biophys. Acta 2007, 1774:93-101.
36. Selicharová I., Smutná K., Sanda M., Ubik K., Matousková E., Bursíková E., Brozová M., Vydra J., Jirácek J. 2-DE analysis of a new human cell line EM-G3 derived from breast cancer progenitor cells and comparison with normal mammary epithelial cells. Proteomics 2007, 7:1549-1559.
37. Liang X., Huuskonen J.K., Hajivandi M., Manzanedo R., Predki P., Amshey J.R., Pope R.M. Identification and quantification of proteins differentially secreted by a pair of normal and malignant breast-cancer cell lines. Proteomics 2009, 9:182-193.
38. Schulz D.M., Böllner C., Thomas G., Atkinson M., Esposito I., Höfler H., Aubele M. Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J. Proteome Res. 2009, 8:3430-3438.
39. Petrak J., Ivanek R., Toman O., Cmejla R., Cmejlova J., Vyoral D., Zivny J., Vulpe C.D. Déjà vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 2008, 8:1744-1749.
40. Pucci-Minafra I., Cancemi P., Fontana S., Minafra L., Feo S., Becch M., Freyria A.M., Minafra S. Expanding the protein catalogue in the proteome reference map of human breast cancer cells. Proteomics 2006, 6:2609-2625.
41. Derry W.B., Wilson L., Jordan M.A. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 1995, 34:2203-2211.
42. Po'uha S., Shum M., Goebel A., Bernard O., Kavallaris M. LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubule-destabilizing drugs. Oncogene 2010, 29:597-607.
43. Bane F.T., Bannon J.H., Pennington S.R., Campaini G., Williams D.C., Zisterer D.M., McGee M.M. The microtubule-targeting agents, PBOX-6 [pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d](1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and pin1, in malignant hematopoietic cells. J. Pharmacol. Exp. Ther. 2009, 329:38-47.
44. Yang Y.X., Sun X.F., Cheng A.L., Zhang G.Y., Yi H., Sun Y., Hu H.D., Hu P., Ye F., Chen Z.C., Xiao Z.Q. Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. J. Cancer Res. Clin. Oncol. 2009, 135:181-189.
45. Ferlini C., Cicchillitti L., Raspaglio G., Bartollino S., Cimitan S., Bertucci C., Mozzetti S., Gallo D., Persico M., Fattorusso C., Campiani G., Scambia G. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009, 69:6906-6914.